FDA clears test to manage potential kidney transplant rejection
The FDA has cleared a test to help manage potential organ rejection in kidney transplant patients.
The FDA has cleared a test to help manage potential organ rejection in kidney transplant patients.
The test, called QMS Everolimus Immunoassay, monitors the blood level of everolimus (Zortress), a drug that helps prevent rejection in kidney transplants.
"QMS Everolimus is the first FDA-cleared test physicians can use to maintain appropriate levels of the immunosuppressant everolimus," said Jeffrey Shuren, MD, JD, director of the FDA’s Center for Devices and Radiological Health.
Thermofisher, the manufacturer of QMS Everolimus, demonstrated the performance of the test by comparing results from the new test with the results from everolimus reference tests used in the clinical trial of everolimus. When the clinical trial blood samples were tested with QMS Everolimus, the results, on average, were similar to those of the clinical trial reference test.
Malpractice Consult: How likely are you to face a medical malpractice lawsuit?
July 23rd 2024"Although there is a good chance that you will face allegations of medical negligence at some point in your career, it is unlikely that you will ever be found liable by a jury," writes Victoria L. Neikam, Esq.
UK study of AI-based software for prostate cancer detection expands
July 22nd 2024"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and patients, and looking at the impact on workflow," says Clare Verrill, BM, FRCPath, MMedEd.
